Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toxicological mechanisms: moving forward with artificial intelligence.

Toxicology mechanisms and methods·2025
Same author

Advancing alternative methods to reduce animal testing.

Science (New York, N.Y.)·2024
Same author

Potential value of animal microphysiological systems.

ALTEX·2024
Same author

Investigative analysis of blood-brain barrier penetrating potential of electronic nicotine delivery systems (e-cigarettes) chemicals using predictive computational models.

Expert opinion on drug metabolism & toxicology·2024
Same author

A Review of the Toxicity of Ingredients in e-Cigarettes, Including Those Ingredients Having the FDA's "Generally Recognized as Safe (GRAS)" Regulatory Status for Use in Food.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco·2024
Same author

A Computational Approach for Respiratory Hazard Identification of Flavor Chemicals in Tobacco Products.

Chemical research in toxicology·2022

Related Experiment Video

Updated: Jun 20, 2026

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
05:47

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox

Published on: August 28, 2019

In silico toxicology for the pharmaceutical sciences.

Luis G Valerio1

  • 1Science and Research Staff, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, White Oak 51 Room 4128, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, USA. Luis.Valerio@fda.hhs.gov

Toxicology and Applied Pharmacology
|September 1, 2009
PubMed
Summary

In silico technologies, or computational toxicology, predict drug safety and metabolism. While promising for pharmaceutical development, further research is needed to address their limitations and ensure accuracy.

More Related Videos

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury
14:20

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury

Published on: June 16, 2018

Related Experiment Videos

Last Updated: Jun 20, 2026

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
05:47

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox

Published on: August 28, 2019

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury
14:20

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury

Published on: June 16, 2018

Area of Science:

  • Computational toxicology and pharmacology
  • Drug discovery and development
  • Chemical risk assessment

Background:

  • In silico technologies, including computational toxicology and predictive ADME, are gaining significant interest for assessing pharmaceutical substances.
  • Increased accessibility and regulatory acceptance are driving the adoption of these tools in scientific research and chemical risk assessment.
  • These methods are crucial for enhancing drug development and ensuring the safety of pharmaceuticals and other xenobiotics.

Purpose of the Study:

  • To critically review the fundamental concepts, current capabilities, and limitations of in silico technologies in toxicology and pharmacology.
  • To explore the application of these tools in predicting preclinical toxicological endpoints, clinical adverse effects, and drug metabolism.
  • To address the reliability and accuracy challenges associated with in silico approaches in drug safety evaluations.

Main Methods:

  • Utilizing specialized software and databases for structure-based screening of active pharmaceutical ingredients and impurities.
  • Employing predictive quantitative structure-activity relationship (QSAR) models for various toxicological endpoints.
  • Reviewing existing literature and research on the application and validation of in silico methods.

Main Results:

  • A wide array of predictive models are available, covering endpoints such as carcinogenicity, genetic toxicity, reproductive toxicity, metabolism, and adverse effects.
  • In silico tools offer potential for enhancing drug discovery and supporting risk assessments for drug-induced toxicities.
  • Significant limitations and the need for further applied research remain critical challenges for these computational approaches.

Conclusions:

  • In silico technologies are valuable tools for pharmaceutical development and safety assessment, but their accuracy requires ongoing statistical and toxicological evaluation.
  • Continued research is essential to overcome current limitations and fully realize the potential of computational toxicology.
  • The judicious application of in silico tools is key to enhancing product development while ensuring scientific rigor and reliability.